ITRM20010408A1 - Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2. - Google Patents

Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2.

Info

Publication number
ITRM20010408A1
ITRM20010408A1 IT2001RM000408A ITRM20010408A ITRM20010408A1 IT RM20010408 A1 ITRM20010408 A1 IT RM20010408A1 IT 2001RM000408 A IT2001RM000408 A IT 2001RM000408A IT RM20010408 A ITRM20010408 A IT RM20010408A IT RM20010408 A1 ITRM20010408 A1 IT RM20010408A1
Authority
IT
Italy
Prior art keywords
antibody
express
cancer cells
erbb2 receptor
erbb2
Prior art date
Application number
IT2001RM000408A
Other languages
English (en)
Inventor
Alessio Giuseppe D
Renata Piccoli
Lorenzo Claudia De
Donald Balfour Palmer
Mary Alice Ritter
Original Assignee
Univ Napoli Federico Ii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Napoli Federico Ii filed Critical Univ Napoli Federico Ii
Priority to IT2001RM000408A priority Critical patent/ITRM20010408A1/it
Publication of ITRM20010408A0 publication Critical patent/ITRM20010408A0/it
Priority to PCT/EP2002/007671 priority patent/WO2003006509A2/en
Priority to DK02784853.0T priority patent/DK1432737T3/da
Priority to SI200230870T priority patent/SI1432737T1/sl
Priority to AT02784853T priority patent/ATE445646T1/de
Priority to PT02784853T priority patent/PT1432737E/pt
Priority to CA002453435A priority patent/CA2453435A1/en
Priority to DE60234041T priority patent/DE60234041D1/de
Priority to ES02784853T priority patent/ES2334895T3/es
Priority to NZ531035A priority patent/NZ531035A/en
Priority to EP02784853A priority patent/EP1432737B1/en
Priority to US10/483,803 priority patent/US7585952B2/en
Publication of ITRM20010408A1 publication Critical patent/ITRM20010408A1/it
Priority to ZA200401044A priority patent/ZA200401044B/en
Priority to US12/506,152 priority patent/US8227585B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IT2001RM000408A 2001-07-10 2001-07-10 Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2. ITRM20010408A1 (it)

Priority Applications (14)

Application Number Priority Date Filing Date Title
IT2001RM000408A ITRM20010408A1 (it) 2001-07-10 2001-07-10 Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2.
US10/483,803 US7585952B2 (en) 2001-07-10 2002-07-10 Human mini-antibody cytotoxic for tumor cells which express the ErbB2 receptor
CA002453435A CA2453435A1 (en) 2001-07-10 2002-07-10 Human mini-antibody cytotoxic for tumor cells which express the erbb2 receptor
ES02784853T ES2334895T3 (es) 2001-07-10 2002-07-10 Mini-anticuerpo humano citotoxico para las celulas tumorales que expresan el receptor erbb2.
SI200230870T SI1432737T1 (sl) 2001-07-10 2002-07-10 Humano mini-protitelo, citotoksično za tumorske celice, ki izražajo ERBB2 receptor
AT02784853T ATE445646T1 (de) 2001-07-10 2002-07-10 Humaner miniantikörper zytotoxisch für tumorzellen die den erbb2 rezeptor exprimieren
PT02784853T PT1432737E (pt) 2001-07-10 2002-07-10 Mini-anticorpo humano citotóxico para células tumorais que expressam o receptor erbb2
PCT/EP2002/007671 WO2003006509A2 (en) 2001-07-10 2002-07-10 Human mini-antibody cytotoxic for tumor cells which express the erbb2 receptor
DE60234041T DE60234041D1 (de) 2001-07-10 2002-07-10 Humaner miniantikörper zytotoxisch für tumorzellen die den erbb2 rezeptor exprimieren
DK02784853.0T DK1432737T3 (da) 2001-07-10 2002-07-10 Humant mini-antistof cytotoxisk for tumorceller der udtrykker ERBB2-receptoren
NZ531035A NZ531035A (en) 2001-07-10 2002-07-10 Human mini-antibody cytotoxic for tumor cells which express the ErbB2 receptor
EP02784853A EP1432737B1 (en) 2001-07-10 2002-07-10 Human mini-antibody cytotoxic for tumor cells which express the erbb2 receptor
ZA200401044A ZA200401044B (en) 2001-07-10 2004-02-09 Human mini-antibody cytotoxic for tumor cells which express the ErbB2 receptor.
US12/506,152 US8227585B2 (en) 2001-07-10 2009-07-20 Human mini-antibody cytotoxic for tumor cells which express the ERBB2 receptor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2001RM000408A ITRM20010408A1 (it) 2001-07-10 2001-07-10 Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2.

Publications (2)

Publication Number Publication Date
ITRM20010408A0 ITRM20010408A0 (it) 2001-07-10
ITRM20010408A1 true ITRM20010408A1 (it) 2003-01-10

Family

ID=11455653

Family Applications (1)

Application Number Title Priority Date Filing Date
IT2001RM000408A ITRM20010408A1 (it) 2001-07-10 2001-07-10 Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2.

Country Status (13)

Country Link
US (2) US7585952B2 (it)
EP (1) EP1432737B1 (it)
AT (1) ATE445646T1 (it)
CA (1) CA2453435A1 (it)
DE (1) DE60234041D1 (it)
DK (1) DK1432737T3 (it)
ES (1) ES2334895T3 (it)
IT (1) ITRM20010408A1 (it)
NZ (1) NZ531035A (it)
PT (1) PT1432737E (it)
SI (1) SI1432737T1 (it)
WO (1) WO2003006509A2 (it)
ZA (1) ZA200401044B (it)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITFI20010114A1 (it) * 2001-06-22 2002-12-22 Univ Firenze Glicopeptidi,loro preparazione e loro uso nella diagnosi o nel trattamento terapeutico della sclerosi multipla
KR20150083139A (ko) 2005-01-21 2015-07-16 제넨테크, 인크. Ｈｅｒ 항체의 고정 용량 투여법
DK1850874T3 (da) 2005-02-23 2013-11-11 Genentech Inc Forlængelse af tid til sygdomsprogression eller overlevelse for ovariecancer ved anvendelse af pertuzumab
ATE547123T1 (de) * 2006-04-21 2012-03-15 Mab Factory Gmbh Antikörper-rnase-konjugat
BRPI0714728A2 (pt) * 2006-08-04 2013-05-14 Astrazeneca Ab agente de ligaÇço alvejado, anticorpo, composiÇço, linhagem de cÉlula isolada molÉcula de Ácido nucleico isolada, vetor, cÉlula hospedeira, mÉtodos para produzir um agente de ligaÇço alvejado, para isolar um anticorpo ou porÇço de ligaÇço de antÍgeno do mesmo, para fabricar um anticorpo monoclonal humano, para tratar, prevenir ou aliviar os sintomas de um distérbio, para inibir a proliferaÇço de uma cÉlula cancerosa, para inibir uma atividade de erbb2 em uma cÉlula que expressa erbb2, e para modular uma atividade de erbb2 em uma cÉlula que expressa erbb2, e, animal transgÊnico nço humano ou planta transgÊnica
NZ578824A (en) 2007-03-02 2012-03-30 Genentech Inc Predicting response to a her dimerisation inhibitor based on low her3 expression
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
SI2171090T1 (sl) 2007-06-08 2013-07-31 Genentech, Inc. Markerji genskega izraĹľanja tumorske odpornosti na HER2 inhibitorsko zdravljenje
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
KR20150036824A (ko) 2009-03-20 2015-04-07 제넨테크, 인크. 이중특이적 항-ｈｅｒ 항체
WO2010136569A1 (en) 2009-05-29 2010-12-02 F. Hoffmann-La Roche Ag Modulators for her2 signaling in her2 expressing patients with gastric cancer
MY160556A (en) 2010-02-18 2017-03-15 Genentech Inc Neuregulin antagonists and use thereof in treating cancer
WO2011119979A2 (en) 2010-03-26 2011-09-29 Memorial Sloan-Kettering Cancer Center Antibodies to muc16 and methods of use thereof
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
US20120148559A1 (en) 2010-12-01 2012-06-14 Board Of Regents The University Of Texas System Compositions and method for deimmunization of proteins
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
CN103890007A (zh) 2011-08-17 2014-06-25 霍夫曼-拉罗奇有限公司 神经调节蛋白抗体及其用途
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
BR112014012979A2 (pt) 2011-11-30 2020-10-20 Genentech, Inc. mutações erbb3 em câncer
EP2788500A1 (en) 2011-12-09 2014-10-15 F.Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
CN104220457A (zh) 2012-03-27 2014-12-17 霍夫曼-拉罗奇有限公司 涉及her3抑制剂的诊断和治疗
BR112015012644A2 (pt) 2012-11-30 2017-12-19 Hoffmann La Roche método para determinar a necessidade de um paciente com câncer, método de tratamento do câncer, composição farmacêutica, uso de um ácido nucleico ou anticorpo e kit;
WO2014200891A1 (en) * 2013-06-11 2014-12-18 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTEMENT OF HEALTH & HUMAN SERVICES Her2-specific monoclonal antibodies and conjugates thereof
CA2922570A1 (en) * 2013-08-26 2015-03-05 Health Research, Inc. Method for prophylaxis and/or treatment of erbb2 positive cancers
EP3129055B1 (en) 2014-04-11 2020-07-01 MedImmune, LLC Bispecific her2 antibodies
ES2890079T3 (es) 2014-05-29 2022-01-17 Macrogenics Inc Moléculas de unión triespecíficas y métodos de uso de las mismas
TWI695011B (zh) * 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗ｈｅｒ２表位之單株抗體及其使用之方法
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
WO2016028956A1 (en) 2014-08-20 2016-02-25 Health Research, Inc. Method for prophylaxis and/or treatment of erbb1 positive cancers
JP6839075B2 (ja) 2014-09-26 2021-03-03 マクロジェニクス，インコーポレーテッド Ｃｄ１９及びｃｄ３に結合できる二重特異性１価ダイアボディ並びにその使用
RU2758113C2 (ru) 2015-03-17 2021-10-26 Мемориал Слоан-Кеттеринг Кэнсер Сентер Антитела к muc16 и их применение
SG10201601719RA (en) 2016-03-04 2017-10-30 Agency Science Tech & Res Anti-LAG-3 Antibodies
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
EP3454863A1 (en) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07309780A (ja) * 1994-03-02 1995-11-28 N Bii T Kk 抗癌剤
US5795961A (en) * 1995-02-14 1998-08-18 Ludwig Institute For Cancer Research Recombinant human anti-Lewis b antibodies
GB9805660D0 (en) * 1998-03-18 1998-05-13 Unichema Chemie Bv Improvements in and relating to fatty acid metabolism
US6135941A (en) 1998-03-27 2000-10-24 Incyte Pharmaceuticals, Inc. Human immune system associated molecules
US7244826B1 (en) * 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
US6794128B2 (en) 1998-04-24 2004-09-21 The Regents Of The University Of California Methods of selecting internalizing antibodies
GB9809280D0 (en) 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
AU6841300A (en) * 1999-08-26 2001-03-19 Morphosys Ag Human antibodies or fragments thereof binding to hla-cw6
AU7676300A (en) * 1999-10-12 2001-04-23 Cambridge Antibody Technology Limited Human anti-adipocyte monoclonal antibodies and their use

Also Published As

Publication number Publication date
ATE445646T1 (de) 2009-10-15
US7585952B2 (en) 2009-09-08
EP1432737A2 (en) 2004-06-30
NZ531035A (en) 2005-04-29
US20100173978A1 (en) 2010-07-08
EP1432737B1 (en) 2009-10-14
WO2003006509A2 (en) 2003-01-23
US20070258985A1 (en) 2007-11-08
SI1432737T1 (sl) 2010-02-26
ES2334895T3 (es) 2010-03-17
ZA200401044B (en) 2004-10-22
WO2003006509A3 (en) 2003-11-20
ITRM20010408A0 (it) 2001-07-10
DK1432737T3 (da) 2010-02-08
CA2453435A1 (en) 2003-01-23
DE60234041D1 (de) 2009-11-26
US8227585B2 (en) 2012-07-24
PT1432737E (pt) 2010-02-17

Similar Documents

Publication Publication Date Title
ITRM20010408A1 (it) Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2.
RS80704A (en) ANTI- av?6.ANTIBODIES
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
TR200102733T2 (tr) IL-18 kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri
BE2016C015I2 (it)
MX2009003838A (es) Anticuerpos anti-cd20 y metodos de uso.
NZ600584A (en) Anti-il 17a/il-17f cross-reactive antibodies and methods of use thereof
WO2004029092A8 (fr) Anticorps pour adcc et induisant la production de cytokines.
US20080038256A1 (en) Anti-hgf/sf humanized antibody and method for the preparation thereof
IL129299A0 (en) Monoclonal antibodies antigens and diagnosis of malignant diseases
WO2006113546A3 (en) Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
RS52889B (sr) Terapijsko humano anti-il-1r1 monoklonsko antitelo
IL226717A (en) Isolated nucleic acids encoded by anti-beta human antibodies 7
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
IN2009KN02655A (it)
SG151284A1 (en) Antibodies against ccr5 and uses thereof
GEP20074222B (en) Antibodies to cd40
TW200510459A (en) RG1 antibodies and uses thereof
MX2009001110A (es) Anticuerpos monoclonales anti-il-6 y usos de los mismos.
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
RS20100555A (en) HUMAN ANTI-NGF NEUTRAL ANTIBODIES AS SELECTIVE NGF SIGNAL ROUTE INHIBITORS
WO2004094473A3 (en) Humanized antibodies to interferon alpha receptor-1 (ifnar-1)
NZ597466A (en) Recombinant anti-epidermal growth factor receptor antibody compositions
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
WO2004108766A3 (en) Anti-hgf-r antibodies and their use